HC Wainwright Issues Positive Forecast for Akero Therapeutics (NASDAQ:AKRO) Stock Price

Akero Therapeutics (NASDAQ:AKRO) had its price target upped by HC Wainwright from $72.00 to $75.00 in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other research analysts also recently commented on AKRO. Canaccord Genuity Group increased their target price on Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $35.00 to $63.00 in a research report on Thursday, January 30th. Morgan Stanley boosted their target price on shares of Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. Citigroup increased their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Finally, UBS Group lifted their price target on Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Akero Therapeutics presently has an average rating of “Buy” and an average target price of $76.29.

Akero Therapeutics Stock Down 7.3 %

AKRO opened at $45.54 on Monday. The company has a market capitalization of $3.18 billion, a PE ratio of -12.14 and a beta of -0.11. The firm has a 50-day simple moving average of $39.27 and a two-hundred day simple moving average of $32.78. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics has a 52 week low of $17.86 and a 52 week high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.01). Analysts forecast that Akero Therapeutics will post -3.99 earnings per share for the current fiscal year.

Insider Activity

In other Akero Therapeutics news, insider Catriona Yale sold 10,000 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $49.87, for a total value of $498,700.00. Following the transaction, the insider now directly owns 95,648 shares in the company, valued at $4,769,965.76. This represents a 9.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Patrick Lamy sold 5,000 shares of Akero Therapeutics stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $57.03, for a total transaction of $285,150.00. Following the sale, the vice president now directly owns 33,492 shares of the company’s stock, valued at $1,910,048.76. This represents a 12.99 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 173,992 shares of company stock valued at $8,509,863. 7.94% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Creative Planning bought a new position in shares of Akero Therapeutics during the 3rd quarter worth $371,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Akero Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after acquiring an additional 446 shares in the last quarter. Victory Capital Management Inc. bought a new position in Akero Therapeutics during the 3rd quarter worth about $211,000. Simplify Asset Management Inc. increased its position in Akero Therapeutics by 15.6% during the 3rd quarter. Simplify Asset Management Inc. now owns 283,766 shares of the company’s stock valued at $8,141,000 after purchasing an additional 38,279 shares during the period. Finally, LMR Partners LLP raised its holdings in shares of Akero Therapeutics by 17.0% in the 3rd quarter. LMR Partners LLP now owns 20,597 shares of the company’s stock valued at $591,000 after purchasing an additional 2,997 shares in the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.